Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Cancer Cachexia (CC) 1

Interventions

Specimen Handling 481pembrolizumab 454Magnetic Resonance Spectroscopy 419Carboplatin 321Cyclophosphamide 314Biopsy 272Cisplatin 264Radiotherapy 239Paclitaxel 226Gemcitabine 222Bevacizumab 212Nivolumab 189fludarabine 183venetoclax 172Drug Therapy 165Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 144Docetaxel 142Standard of Care 136Radiosurgery 136Rituximab 125Pemetrexed 115durvalumab 113atezolizumab 110Leucovorin 110Radiation 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × alkaloid GB18 × 1 year × Clear all
NCT07237464 2025-11-19

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants

Kexing Biopharm Co., Ltd.

Phase 1 Recruiting
36 enrolled

Cancer Cachexia (CC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡